Abstract:
Disclosed are polarization-independent electro-optical compositions using dichroic-dye-doped polymer stabilized optically isotropic chiral liquid crystals. The isotropic phase of such compositions can be well maintained even if the temperature is below 0° C. The electro-optical performances of such compositions demonstrate large Kerr constants, fast response times, and large contrast ratios of the compositions. The power consumption and the cost of devices based on the compositions can be decreased substantially due to alignment-free and polarizer-free characteristics. The compositions can be used to generate low power consumption displays and other photonic devices.
Abstract:
Methods of making metal oxide-graphene composites are disclosed. The methods can include, for example, providing a composition including graphene oxide and at least one substrate, the composition being dispersed in a liquid medium. The methods can also include, for example, providing a composition including graphene oxide and at least one substrate, heating the composition, and cooling the composition. Compositions useful for performing the methods and composites obtained by the process are also disclosed.
Abstract:
Disclosed is the use of a fusion protein in drugs for stimulating differentiation of bone marrow mesenchymal stem cells to hematopoietic stem/progenitor cells, or drugs for proliferation of granulocyte hematopoietic progenitor cells. The fusion protein has a sequence as shown in SEQ ID NO: 2 or SEQ ID NO: 4. The drugs can be used for the prevention and/or treatment of (i) hematopoietic dysfunction caused by chemotherapy, (ii) hematopoietic dysfunction caused by radiotherapy, or (iii) leukopenia.
Abstract translation:公开了在药物中使用融合蛋白来刺激骨髓间充质干细胞分化成造血干细胞/祖细胞或用于粒细胞造血祖细胞增殖的药物。 融合蛋白具有如SEQ ID NO:2或SEQ ID NO:4所示的序列。该药物可用于预防和/或治疗(i)由化疗引起的造血功能障碍,(ii)造血功能障碍引起的 放射治疗,或(iii)白细胞减少。
Abstract:
Provided are a pteridine ketone derivative used as an EGFR, BLK, and FLT3 inhibitor and applications thereof. Specifically, provided are a compound of the following formula I, a pharmaceutical composition containing the compound of the formula I, and use of compound in preparing medicine for treating diseases mediated by EGFR, BLK, or FLT3 or inhibiting EGFR, BLK, and FLT3.
Abstract:
A blue phase liquid crystal material includes a liquid crystal host, a chiral reagent and a stable polymer. The chiral reagent is R811. The stable polymer is formed by photo-polymerizing a first monomer and a second monomer. The first monomer is 2-ethylhexyl acrylate (2-EHA), and the second monomer is 2-methyl-1,4-bis{4-[3(-acrylate)propoxyl]benzoicacid}phenylester (PTPTP). The blue phase liquid crystal material has a blue phase temperature range widened to an extremely low temperature. A blue phase liquid crystal composition and a method for manufacturing the blue phase liquid crystal material by using the blue phase liquid crystal composition are also provided.
Abstract:
Provided are a twist-bend nematic (NTB) LC dimer-based material and use thereof, and an LC-based cholesteric heliconical (CH) material and use thereof. The NTB LC dimer-based material is at least one selected from the group consisting of CBnCB, CBnOCB, and CBOnOCB, with n being a positive integer of 3 to 15. Based on ultra-stable properties of the material, the disclosure further provides the LC-based CH material, which uses the LC dimer-based material as a key raw material and integrates a conventional nematic LC monomer material and a chiral molecule.
Abstract:
The disclosure provides a precursor solution, a perovskite solar cell and a preparation method thereof. The solute of the precursor solution includes a metal halide, the solvent of the precursor solution is an organic solvent, and the precursor solution contains nanobubbles, which have a diameter not more than 1000 nm, and the zeta potential of the precursor solution does not exceed-20 mV. The method of preparing the precursor solution includes: (1) preparing an organic solvent containing nanobubbles; (2) dissolving a solute in the organic solvent containing nanobubbles. The precursor solution of the disclosure has a very low zeta potential, and the nanobubbles can exist stably in the organic solvent(s) for up to one month. When comparing with traditional methods for preparing the precursor solution of the perovskite cells, the method for preparing the precursor solution of the disclosure can effectively improve the stability, reproducibility and solubility of the metal halide in the organic solvent(s).
Abstract:
A double-sided ultrasonic rolling cooperative strengthening system and a control method thereof are provided. The system includes a first mechanical arm subsystem, a second mechanical arm subsystem, a first ultrasonic rolling strengthening subsystem, a second ultrasonic rolling strengthening subsystem and a servo turntable (13); the servo turntable (13) is configured to fix a blade to be processed; the first ultrasonic rolling strengthening subsystem is provided at an end of the first mechanical arm subsystem; and the second ultrasonic rolling strengthening subsystem is provided at an end of the second mechanical arm subsystem. The way that the mechanical arm is equipped with an ultrasonic rolling strengthening device improves a degree of freedom of processing the blade, and the first mechanical arm subsystem, the second mechanical arm subsystem, the first ultrasonic rolling strengthening subsystem, the second ultrasonic rolling strengthening subsystem and the servo turntable (13) are provided to cooperate to realize double-sided processing.
Abstract:
An efficient and economical method for synthesizing Fasudil hydrochloride includes the synthesis route starts with inexpensive and readily available ethylenediamine as the starting material, obtains intermediate tert butyl-(N-(2-aminoethyl)-5-isoquinoline sulfonamide) carbamate (5) through sulfonylation and Boc protection, and then obtains Fasudil hydrochloride through a stacking process, which includes four steps: nucleophilic substitution, deprotection, cyclization, and salt formation. The total yield of Fasudil hydrochloride (1) is 67.1%, with a purity of up to 99.94%. Compared with traditional processes, the route avoids the use of expensive homopiperazine and its derivatives as synthetic intermediates. The advantages of the process include cheap and easy to obtain raw materials, simple operation, low cost, environmental friendliness, and suitability for industrial production.
Abstract:
The present application provides an on-machine point cloud detection and compensation method for processing complex surfaces, which comprises: step S1, installing a detecting and scanning actuator on an ultrasonic rolling machine tool; step S2, installing a processed workpiece on the chuck which is scanned by the detecting and scanning actuator to obtain the point cloud data of the workpiece in a coordinate system of detecting and scanning actuator, which is converted into the point cloud data of the workpiece in a coordinate system of machine tool; step S3, processing the point cloud data of the workpiece in the coordinate system of machine tool; step S4, obtaining and compensating the shape error feature of the workpiece according to theoretical design data of the processed workpiece and processed point cloud data of the workpiece in the coordinate system of machine tool. The accuracy and efficiency of complex surface strengthening is improved in the present application.